$GILD Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in GILEAD SCIENCES INC.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in GILEAD SCIENCES INC. Get notifications about new insider transactions in GILEAD SCIENCES INC for free.
Page: < prev 1 ... 4 5 6 7 8 9 10 11 12 ... 46 next >
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Mar 03 2016 | GILD | GILEAD SCIENCES IN ... | Washington Robin L | EVP, CFO | Buy | J | 0.00 | 28,280 | 0 | 112,968 | 84.7 K to 113 K (+33.39 %) |
Feb 29 2016 | GILD | GILEAD SCIENCES IN ... | WILSON GAYLE E | Director | Option Exercise | M | 20.71 | 6,650 | 137,688 | 33,350 | |
Feb 29 2016 | GILD | GILEAD SCIENCES IN ... | WILSON GAYLE E | Director | Sell | S | 90.61 | 6,650 | 602,557 | 103,873 | 110.5 K to 103.9 K (-6.02 %) |
Feb 29 2016 | GILD | GILEAD SCIENCES IN ... | WILSON GAYLE E | Director | Buy | M | 20.71 | 6,650 | 137,688 | 110,523 | 103.9 K to 110.5 K (+6.40 %) |
Feb 18 2016 | GILD | GILEAD SCIENCES IN ... | Washington Robin L | EVP, CFO | Sell | S | 90.72 | 6,250 | 567,000 | 84,688 | 90.9 K to 84.7 K (-6.87 %) |
Feb 18 2016 | GILD | GILEAD SCIENCES IN ... | Washington Robin L | EVP, CFO | Payment of Exercise | F | 91.15 | 26,808 | 2,443,549 | 49,484 | 76.3 K to 49.5 K (-35.14 %) |
Feb 18 2016 | GILD | GILEAD SCIENCES IN ... | Washington Robin L | EVP, CFO | Grant | A | 0.00 | 35,174 | 0 | 76,292 | 41.1 K to 76.3 K (+85.54 %) |
Feb 18 2016 | GILD | GILEAD SCIENCES IN ... | Washington Robin L | EVP, CFO | Grant | A | 0.00 | 13,146 | 0 | 41,118 | 28 K to 41.1 K (+47.00 %) |
Feb 18 2016 | GILD | GILEAD SCIENCES IN ... | Washington Robin L | EVP, CFO | Grant | A | 76.02 | 248 | 18,854 | 27,972 | 27.7 K to 28 K (+0.89 %) |
Feb 18 2016 | GILD | GILEAD SCIENCES IN ... | MILLIGAN JOHN F | President, COO and ... | Payment of Exercise | F | 91.15 | 45,433 | 4,141,218 | 1,058,963 | 1.1 M to 1.1 M (-4.11 %) |
Feb 18 2016 | GILD | GILEAD SCIENCES IN ... | MILLIGAN JOHN F | President, COO and ... | Grant | A | 0.00 | 58,794 | 0 | 1,104,396 | 1 M to 1.1 M (+5.62 %) |
Feb 18 2016 | GILD | GILEAD SCIENCES IN ... | MILLIGAN JOHN F | President, COO and ... | Grant | A | 0.00 | 16,246 | 0 | 1,045,602 | 1 M to 1 M (+1.58 %) |
Feb 18 2016 | GILD | GILEAD SCIENCES IN ... | MILLIGAN JOHN F | President, COO and ... | Grant | A | 76.02 | 248 | 18,854 | 1,029,356 | 1 M to 1 M (+0.02 %) |
Feb 18 2016 | GILD | GILEAD SCIENCES IN ... | MARTIN JOHN C | Chairman and CEO | Payment of Exercise | F | 91.19 | 122,901 | 11,207,342 | 4,019,727 | 4.1 M to 4 M (-2.97 %) |
Feb 18 2016 | GILD | GILEAD SCIENCES IN ... | MARTIN JOHN C | Chairman and CEO | Grant | A | 0.00 | 154,328 | 0 | 4,142,628 | 4 M to 4.1 M (+3.87 %) |
Feb 18 2016 | GILD | GILEAD SCIENCES IN ... | MARTIN JOHN C | Chairman and CEO | Grant | A | 0.00 | 39,986 | 0 | 3,988,300 | 3.9 M to 4 M (+1.01 %) |
Feb 18 2016 | GILD | GILEAD SCIENCES IN ... | MARTIN JOHN C | Chairman and CEO | Grant | A | 76.02 | 248 | 18,854 | 3,948,314 | 3.9 M to 3.9 M (+0.01 %) |
Feb 18 2016 | GILD | GILEAD SCIENCES IN ... | Carter Paul Rutherford | EVP Commercial Ops | Payment of Exercise | F | 91.15 | 7,395 | 674,054 | 61,122 | 68.5 K to 61.1 K (-10.79 %) |
Feb 18 2016 | GILD | GILEAD SCIENCES IN ... | Carter Paul Rutherford | EVP Commercial Ops | Grant | A | 0.00 | 9,554 | 0 | 68,517 | 59 K to 68.5 K (+16.20 %) |
Feb 18 2016 | GILD | GILEAD SCIENCES IN ... | Carter Paul Rutherford | EVP Commercial Ops | Grant | A | 0.00 | 9,932 | 0 | 58,963 | 49 K to 59 K (+20.26 %) |
Feb 18 2016 | GILD | GILEAD SCIENCES IN ... | Carter Paul Rutherford | EVP Commercial Ops | Grant | A | 76.02 | 248 | 18,854 | 49,031 | 48.8 K to 49 K (+0.51 %) |
Feb 18 2016 | GILD | GILEAD SCIENCES IN ... | BISCHOFBERGER NORBERT W | EVP, R&D and CSO | Payment of Exercise | F | 91.15 | 40,716 | 3,711,263 | 191,940 | 232.7 K to 191.9 K (-17.50 %) |
Feb 18 2016 | GILD | GILEAD SCIENCES IN ... | BISCHOFBERGER NORBERT W | EVP, R&D and CSO | Grant | A | 0.00 | 52,914 | 0 | 232,656 | 179.7 K to 232.7 K (+29.44 %) |
Feb 18 2016 | GILD | GILEAD SCIENCES IN ... | BISCHOFBERGER NORBERT W | EVP, R&D and CSO | Grant | A | 0.00 | 14,326 | 0 | 179,742 | 165.4 K to 179.7 K (+8.66 %) |
Feb 18 2016 | GILD | GILEAD SCIENCES IN ... | BISCHOFBERGER NORBERT W | EVP, R&D and CSO | Grant | A | 76.02 | 248 | 18,854 | 165,416 | 165.2 K to 165.4 K (+0.15 %) |
Feb 18 2016 | GILD | GILEAD SCIENCES IN ... | Alton Gregg H | EVP, Corp & Med Af ... | Payment of Exercise | F | 91.15 | 32,786 | 2,988,444 | 152,090 | 184.9 K to 152.1 K (-17.73 %) |
Feb 18 2016 | GILD | GILEAD SCIENCES IN ... | Alton Gregg H | EVP, Corp & Med Af ... | Grant | A | 0.00 | 42,614 | 0 | 184,876 | 142.3 K to 184.9 K (+29.95 %) |
Feb 18 2016 | GILD | GILEAD SCIENCES IN ... | Alton Gregg H | EVP, Corp & Med Af ... | Grant | A | 0.00 | 12,592 | 0 | 142,262 | 129.7 K to 142.3 K (+9.71 %) |
Feb 18 2016 | GILD | GILEAD SCIENCES IN ... | Alton Gregg H | EVP, Corp & Med Af ... | Grant | A | 76.02 | 248 | 18,854 | 129,670 | 129.4 K to 129.7 K (+0.19 %) |
Feb 03 2016 | GILD | GILEAD SCIENCES IN ... | Washington Robin L | EVP, CFO | Option Exercise | A | 84.05 | 68,600 | 5,765,830 | 68,600 | |
Feb 03 2016 | GILD | GILEAD SCIENCES IN ... | MILLIGAN JOHN F | President and COO | Option Exercise | A | 84.05 | 235,820 | 19,820,671 | 235,820 | |
Feb 03 2016 | GILD | GILEAD SCIENCES IN ... | BISCHOFBERGER NORBERT W | EVP, R&D and CSO | Option Exercise | A | 84.05 | 85,750 | 7,207,288 | 85,750 | |
Feb 03 2016 | GILD | GILEAD SCIENCES IN ... | MARTIN JOHN C | Chairman and CEO | Option Exercise | A | 84.05 | 128,630 | 10,811,352 | 128,630 | |
Feb 03 2016 | GILD | GILEAD SCIENCES IN ... | MARTIN JOHN C | Chairman and CEO | Option Exercise | M | 16.40 | 100,000 | 1,639,500 | 1,000,000 | |
Feb 03 2016 | GILD | GILEAD SCIENCES IN ... | MARTIN JOHN C | Chairman and CEO | Sell | S | 84.35 | 400 | 33,739 | 3,948,066 | 3.9 M to 3.9 M (-0.01 %) |
Feb 03 2016 | GILD | GILEAD SCIENCES IN ... | MARTIN JOHN C | Chairman and CEO | Sell | S | 83.77 | 55,973 | 4,688,590 | 3,948,466 | 4 M to 3.9 M (-1.40 %) |
Feb 03 2016 | GILD | GILEAD SCIENCES IN ... | MARTIN JOHN C | Chairman and CEO | Sell | S | 82.98 | 43,627 | 3,620,147 | 4,004,439 | 4 M to 4 M (-1.08 %) |
Feb 03 2016 | GILD | GILEAD SCIENCES IN ... | MARTIN JOHN C | Chairman and CEO | Buy | M | 16.40 | 100,000 | 1,639,500 | 4,048,066 | 3.9 M to 4 M (+2.53 %) |
Feb 03 2016 | GILD | GILEAD SCIENCES IN ... | Carter Paul Rutherford | EVP Commercial Ops | Option Exercise | A | 84.05 | 42,880 | 3,604,064 | 42,880 | |
Feb 03 2016 | GILD | GILEAD SCIENCES IN ... | Carter Paul Rutherford | EVP Commercial Ops | Option Exercise | M | 40.56 | 1,818 | 73,738 | 8,437 | |
Feb 03 2016 | GILD | GILEAD SCIENCES IN ... | Carter Paul Rutherford | EVP Commercial Ops | Option Exercise | M | 24.91 | 182 | 4,533 | 38,641 | |
Feb 03 2016 | GILD | GILEAD SCIENCES IN ... | Carter Paul Rutherford | EVP Commercial Ops | Sell | S | 82.32 | 2,000 | 164,640 | 48,783 | 50.8 K to 48.8 K (-3.94 %) |
Feb 03 2016 | GILD | GILEAD SCIENCES IN ... | Carter Paul Rutherford | EVP Commercial Ops | Buy | M | 40.56 | 1,818 | 73,738 | 50,783 | 49 K to 50.8 K (+3.71 %) |
Feb 03 2016 | GILD | GILEAD SCIENCES IN ... | Carter Paul Rutherford | EVP Commercial Ops | Buy | M | 24.91 | 182 | 4,533 | 48,965 | 48.8 K to 49 K (+0.37 %) |
Feb 03 2016 | GILD | GILEAD SCIENCES IN ... | Alton Gregg H | EVP, Corp & Med Af ... | Option Exercise | A | 84.05 | 75,030 | 6,306,272 | 75,030 | |
Apr 21 2016 | GILD | GILEAD SCIENCES IN ... | Alton Gregg H | EVP, Corp & Med Af ... | Option Exercise | M | 26.99 | 35,874 | 968,239 | 64,126 | |
Apr 21 2016 | GILD | GILEAD SCIENCES IN ... | Alton Gregg H | EVP, Corp & Med Af ... | Sell | S | 100.00 | 4,126 | 412,600 | 137,964 | 142.1 K to 138 K (-2.90 %) |
Apr 21 2016 | GILD | GILEAD SCIENCES IN ... | Alton Gregg H | EVP, Corp & Med Af ... | Sell | S | 100.02 | 35,874 | 3,587,974 | 142,090 | 178 K to 142.1 K (-20.16 %) |
Apr 21 2016 | GILD | GILEAD SCIENCES IN ... | Alton Gregg H | EVP, Corp & Med Af ... | Buy | M | 26.99 | 35,874 | 968,239 | 177,964 | 142.1 K to 178 K (+25.25 %) |
Jan 06 2016 | GILD | GILEAD SCIENCES IN ... | MARTIN JOHN C | Chairman and CEO | Option Exercise | M | 16.40 | 100,000 | 1,639,500 | 1,100,000 | |
Jan 06 2016 | GILD | GILEAD SCIENCES IN ... | MARTIN JOHN C | Chairman and CEO | Sell | S | 99.49 | 2,750 | 273,588 | 3,948,066 | 4 M to 3.9 M (-0.07 %) |
Jan 06 2016 | GILD | GILEAD SCIENCES IN ... | MARTIN JOHN C | Chairman and CEO | Sell | S | 98.35 | 10,969 | 1,078,755 | 3,950,816 | 4 M to 4 M (-0.28 %) |
Jan 06 2016 | GILD | GILEAD SCIENCES IN ... | MARTIN JOHN C | Chairman and CEO | Sell | S | 97.53 | 86,281 | 8,415,366 | 3,961,785 | 4 M to 4 M (-2.13 %) |
Jan 06 2016 | GILD | GILEAD SCIENCES IN ... | MARTIN JOHN C | Chairman and CEO | Buy | M | 16.40 | 100,000 | 1,639,500 | 4,048,066 | 3.9 M to 4 M (+2.53 %) |
Jan 06 2016 | GILD | GILEAD SCIENCES IN ... | Carter Paul Rutherford | EVP Commercial Ops | Option Exercise | M | 26.99 | 823 | 22,213 | 0 | |
Jan 06 2016 | GILD | GILEAD SCIENCES IN ... | Carter Paul Rutherford | EVP Commercial Ops | Option Exercise | M | 24.91 | 1,177 | 29,313 | 38,823 | |
Jan 06 2016 | GILD | GILEAD SCIENCES IN ... | Carter Paul Rutherford | EVP Commercial Ops | Sell | S | 99.20 | 2,000 | 198,400 | 48,783 | 50.8 K to 48.8 K (-3.94 %) |
Jan 06 2016 | GILD | GILEAD SCIENCES IN ... | Carter Paul Rutherford | EVP Commercial Ops | Buy | M | 24.91 | 1,177 | 29,313 | 50,783 | 49.6 K to 50.8 K (+2.37 %) |
Jan 06 2016 | GILD | GILEAD SCIENCES IN ... | Carter Paul Rutherford | EVP Commercial Ops | Buy | M | 26.99 | 823 | 22,213 | 49,606 | 48.8 K to 49.6 K (+1.69 %) |
Jan 04 2016 | GILD | GILEAD SCIENCES IN ... | MOORE NICHOLAS G | Director | Option Exercise | A | 0.00 | 103 | 0 | 24,612 | |
Jan 04 2016 | GILD | GILEAD SCIENCES IN ... | Whitley Richard James | Director | Option Exercise | A | 0.00 | 26 | 0 | 6,167 | |
Jan 04 2016 | GILD | GILEAD SCIENCES IN ... | Lofton Kevin E | Director | Option Exercise | A | 0.00 | 78 | 0 | 18,573 | |
Jan 04 2016 | GILD | GILEAD SCIENCES IN ... | HILLS CARLA A | Director | Option Exercise | A | 0.00 | 9 | 0 | 2,159 | |
Jan 04 2016 | GILD | GILEAD SCIENCES IN ... | WILSON GAYLE E | Director | Option Exercise | A | 0.00 | 9 | 0 | 2,115 | |
Dec 17 2015 | GILD | GILEAD SCIENCES IN ... | BISCHOFBERGER NORBERT W | EVP, R&D and CSO | Option Exercise | M | 23.76 | 43,600 | 1,035,718 | 28,800 | |
Dec 17 2015 | GILD | GILEAD SCIENCES IN ... | BISCHOFBERGER NORBERT W | EVP, R&D and CSO | Option Exercise | M | 19.09 | 26,400 | 503,844 | 211,600 | |
Dec 17 2015 | GILD | GILEAD SCIENCES IN ... | BISCHOFBERGER NORBERT W | EVP, R&D and CSO | Sell | S | 102.22 | 39,569 | 4,044,783 | 127,936 | 167.5 K to 127.9 K (-23.62 %) |
Dec 17 2015 | GILD | GILEAD SCIENCES IN ... | BISCHOFBERGER NORBERT W | EVP, R&D and CSO | Sell | S | 102.66 | 30,431 | 3,123,958 | 167,505 | 197.9 K to 167.5 K (-15.37 %) |
Dec 17 2015 | GILD | GILEAD SCIENCES IN ... | BISCHOFBERGER NORBERT W | EVP, R&D and CSO | Buy | M | 19.09 | 26,400 | 503,844 | 197,936 | 171.5 K to 197.9 K (+15.39 %) |
Dec 17 2015 | GILD | GILEAD SCIENCES IN ... | BISCHOFBERGER NORBERT W | EVP, R&D and CSO | Buy | M | 23.76 | 43,600 | 1,035,718 | 171,536 | 127.9 K to 171.5 K (+34.08 %) |
Dec 09 2015 | GILD | GILEAD SCIENCES IN ... | MILLIGAN JOHN F | President and COO | Option Exercise | M | 14.50 | 100,000 | 1,450,250 | 0 | |
Dec 09 2015 | GILD | GILEAD SCIENCES IN ... | MILLIGAN JOHN F | President and COO | Sell | S | 103.56 | 39,355 | 4,075,490 | 1,029,108 | 1.1 M to 1 M (-3.68 %) |
Dec 09 2015 | GILD | GILEAD SCIENCES IN ... | MILLIGAN JOHN F | President and COO | Sell | S | 102.94 | 60,645 | 6,242,487 | 1,068,463 | 1.1 M to 1.1 M (-5.37 %) |
Dec 09 2015 | GILD | GILEAD SCIENCES IN ... | MILLIGAN JOHN F | President and COO | Buy | M | 14.50 | 100,000 | 1,450,250 | 1,129,108 | 1 M to 1.1 M (+9.72 %) |
Dec 03 2015 | GILD | GILEAD SCIENCES IN ... | WILSON GAYLE E | Director | Option Exercise | M | 0.00 | 2,106 | 0 | 2,106 | |
Dec 03 2015 | GILD | GILEAD SCIENCES IN ... | WILSON GAYLE E | Director | Buy | M | 0.00 | 2,104 | 0 | 103,873 | 101.8 K to 103.9 K (+2.07 %) |
Dec 03 2015 | GILD | GILEAD SCIENCES IN ... | MARTIN JOHN C | Chairman and CEO | Option Exercise | M | 14.50 | 150,000 | 2,175,375 | 0 | |
Dec 03 2015 | GILD | GILEAD SCIENCES IN ... | MARTIN JOHN C | Chairman and CEO | Sell | S | 107.01 | 20,530 | 2,196,843 | 3,948,066 | 4 M to 3.9 M (-0.52 %) |
Dec 03 2015 | GILD | GILEAD SCIENCES IN ... | MARTIN JOHN C | Chairman and CEO | Sell | S | 106.14 | 49,284 | 5,230,752 | 3,968,596 | 4 M to 4 M (-1.23 %) |
Dec 03 2015 | GILD | GILEAD SCIENCES IN ... | MARTIN JOHN C | Chairman and CEO | Sell | S | 105.33 | 80,186 | 8,445,871 | 4,017,880 | 4.1 M to 4 M (-1.96 %) |
Dec 03 2015 | GILD | GILEAD SCIENCES IN ... | MARTIN JOHN C | Chairman and CEO | Buy | M | 14.50 | 150,000 | 2,175,375 | 4,098,066 | 3.9 M to 4.1 M (+3.80 %) |
Dec 03 2015 | GILD | GILEAD SCIENCES IN ... | Alton Gregg H | EVP, Corp & Med Af ... | Option Exercise | M | 24.30 | 10,000 | 242,950 | 108,742 | |
Dec 03 2015 | GILD | GILEAD SCIENCES IN ... | Alton Gregg H | EVP, Corp & Med Af ... | Sell | S | 107.18 | 1,300 | 139,330 | 129,422 | 130.7 K to 129.4 K (-0.99 %) |
Dec 03 2015 | GILD | GILEAD SCIENCES IN ... | Alton Gregg H | EVP, Corp & Med Af ... | Sell | S | 106.54 | 4,705 | 501,264 | 130,722 | 135.4 K to 130.7 K (-3.47 %) |
Dec 03 2015 | GILD | GILEAD SCIENCES IN ... | Alton Gregg H | EVP, Corp & Med Af ... | Sell | S | 105.35 | 5,995 | 631,564 | 135,427 | 141.4 K to 135.4 K (-4.24 %) |
Dec 03 2015 | GILD | GILEAD SCIENCES IN ... | Alton Gregg H | EVP, Corp & Med Af ... | Buy | M | 24.30 | 10,000 | 242,950 | 141,422 | 131.4 K to 141.4 K (+7.61 %) |
Dec 03 2015 | GILD | GILEAD SCIENCES IN ... | Carter Paul Rutherford | EVP Commercial Ops | Option Exercise | M | 26.99 | 2,000 | 53,980 | 823 | |
Dec 03 2015 | GILD | GILEAD SCIENCES IN ... | Carter Paul Rutherford | EVP Commercial Ops | Sell | S | 106.38 | 2,000 | 212,760 | 48,783 | 50.8 K to 48.8 K (-3.94 %) |
Dec 03 2015 | GILD | GILEAD SCIENCES IN ... | Carter Paul Rutherford | EVP Commercial Ops | Buy | M | 26.99 | 2,000 | 53,980 | 50,783 | 48.8 K to 50.8 K (+4.10 %) |
Nov 25 2015 | GILD | GILEAD SCIENCES IN ... | Whitley Richard James | Director | Gift | G | 0.00 | 7,050 | 0 | 23,669 | 30.7 K to 23.7 K (-22.95 %) |
Nov 25 2015 | GILD | GILEAD SCIENCES IN ... | Whitley Richard James | Director | Sell | S | 106.48 | 169 | 17,995 | 30,719 | 30.9 K to 30.7 K (-0.55 %) |
Nov 25 2015 | GILD | GILEAD SCIENCES IN ... | Whitley Richard James | Director | Sell | S | 107.18 | 2,863 | 306,845 | 30,888 | 33.8 K to 30.9 K (-8.48 %) |
Nov 25 2015 | GILD | GILEAD SCIENCES IN ... | Whitley Richard James | Director | Sell | S | 106.99 | 5,514 | 589,917 | 33,751 | 39.3 K to 33.8 K (-14.04 %) |
Nov 25 2015 | GILD | GILEAD SCIENCES IN ... | Cogan John Francis | Director | Option Exercise | M | 20.71 | 15,000 | 310,575 | 15,000 | |
Nov 25 2015 | GILD | GILEAD SCIENCES IN ... | Cogan John Francis | Director | Sell | S | 105.95 | 15,000 | 1,589,190 | 44,309 | 59.3 K to 44.3 K (-25.29 %) |
Nov 25 2015 | GILD | GILEAD SCIENCES IN ... | Cogan John Francis | Director | Buy | M | 20.71 | 15,000 | 310,575 | 59,309 | 44.3 K to 59.3 K (+33.85 %) |
Nov 18 2015 | GILD | GILEAD SCIENCES IN ... | BISCHOFBERGER NORBERT W | EVP, R&D and CSO | Option Exercise | M | 23.76 | 70,000 | 1,662,850 | 72,400 | |
Nov 18 2015 | GILD | GILEAD SCIENCES IN ... | BISCHOFBERGER NORBERT W | EVP, R&D and CSO | Sell | S | 103.79 | 5,544 | 575,396 | 165,168 | 170.7 K to 165.2 K (-3.25 %) |
Nov 18 2015 | GILD | GILEAD SCIENCES IN ... | BISCHOFBERGER NORBERT W | EVP, R&D and CSO | Sell | S | 103.26 | 18,981 | 1,959,881 | 170,712 | 189.7 K to 170.7 K (-10.01 %) |
Nov 18 2015 | GILD | GILEAD SCIENCES IN ... | BISCHOFBERGER NORBERT W | EVP, R&D and CSO | Sell | S | 102.26 | 45,475 | 4,650,142 | 189,693 | 235.2 K to 189.7 K (-19.34 %) |
Nov 18 2015 | GILD | GILEAD SCIENCES IN ... | BISCHOFBERGER NORBERT W | EVP, R&D and CSO | Buy | M | 23.76 | 70,000 | 1,662,850 | 235,168 | 165.2 K to 235.2 K (+42.38 %) |
Nov 13 2015 | GILD | GILEAD SCIENCES IN ... | BISCHOFBERGER NORBERT W | EVP, R&D and CSO | Gift | G | 0.00 | 5,000 | 0 | 2,149,681 | 2.2 M to 2.1 M (-0.23 %) |
Nov 12 2015 | GILD | GILEAD SCIENCES IN ... | Washington Robin L | EVP, CFO | Grant | A | 0.00 | 2,892 | 0 | 90,938 | 88 K to 90.9 K (+3.28 %) |
Nov 12 2015 | GILD | GILEAD SCIENCES IN ... | Washington Robin L | EVP, CFO | Gift | G | 0.00 | 2,892 | 0 | 27,724 | 30.6 K to 27.7 K (-9.45 %) |
Nov 12 2015 | GILD | GILEAD SCIENCES IN ... | MILLIGAN JOHN F | President and COO | Option Exercise | M | 14.50 | 100,000 | 1,450,250 | 100,000 | |
Nov 12 2015 | GILD | GILEAD SCIENCES IN ... | MILLIGAN JOHN F | President and COO | Sell | S | 108.27 | 8,509 | 921,267 | 1,029,108 | 1 M to 1 M (-0.82 %) |
Nov 12 2015 | GILD | GILEAD SCIENCES IN ... | MILLIGAN JOHN F | President and COO | Sell | S | 107.60 | 91,491 | 9,844,377 | 1,037,617 | 1.1 M to 1 M (-8.10 %) |
Nov 12 2015 | GILD | GILEAD SCIENCES IN ... | MILLIGAN JOHN F | President and COO | Buy | M | 14.50 | 100,000 | 1,450,250 | 1,129,108 | 1 M to 1.1 M (+9.72 %) |
Nov 09 2015 | GILD | GILEAD SCIENCES IN ... | Washington Robin L | EVP, CFO | Option Exercise | M | 0.00 | 6,000 | 0 | 0 | |
Nov 09 2015 | GILD | GILEAD SCIENCES IN ... | Washington Robin L | EVP, CFO | Payment of Exercise | F | 107.83 | 3,108 | 335,136 | 30,616 | 33.7 K to 30.6 K (-9.22 %) |
Nov 09 2015 | GILD | GILEAD SCIENCES IN ... | Washington Robin L | EVP, CFO | Buy | M | 0.00 | 6,000 | 0 | 33,724 | 27.7 K to 33.7 K (+21.64 %) |
Nov 04 2015 | GILD | GILEAD SCIENCES IN ... | Carter Paul Rutherford | EVP Commercial Ops | Option Exercise | M | 40.56 | 1,816 | 73,657 | 10,255 | |
Nov 04 2015 | GILD | GILEAD SCIENCES IN ... | Carter Paul Rutherford | EVP Commercial Ops | Option Exercise | M | 26.99 | 184 | 4,966 | 2,823 | |
Nov 04 2015 | GILD | GILEAD SCIENCES IN ... | Carter Paul Rutherford | EVP Commercial Ops | Sell | S | 108.36 | 2,000 | 216,712 | 48,783 | 50.8 K to 48.8 K (-3.94 %) |
Nov 04 2015 | GILD | GILEAD SCIENCES IN ... | Carter Paul Rutherford | EVP Commercial Ops | Sell | M | 40.56 | 1,816 | 73,657 | 50,783 | 52.6 K to 50.8 K (-3.45 %) |
Nov 04 2015 | GILD | GILEAD SCIENCES IN ... | Carter Paul Rutherford | EVP Commercial Ops | Sell | M | 26.99 | 184 | 4,966 | 48,967 | 49.2 K to 49 K (-0.37 %) |
Nov 04 2015 | GILD | GILEAD SCIENCES IN ... | Washington Robin L | EVP, CFO | Sell | S | 109.61 | 4,350 | 476,806 | 88,046 | 92.4 K to 88 K (-4.71 %) |
Nov 04 2015 | GILD | GILEAD SCIENCES IN ... | Washington Robin L | EVP, CFO | Sell | S | 109.13 | 1,900 | 207,344 | 92,396 | 94.3 K to 92.4 K (-2.01 %) |
Nov 04 2015 | GILD | GILEAD SCIENCES IN ... | Alton Gregg H | EVP, Corp & Med Af ... | Option Exercise | M | 24.30 | 10,000 | 242,950 | 118,742 | |
Nov 04 2015 | GILD | GILEAD SCIENCES IN ... | Alton Gregg H | EVP, Corp & Med Af ... | Sell | S | 109.67 | 5,860 | 642,642 | 131,422 | 137.3 K to 131.4 K (-4.27 %) |
Nov 04 2015 | GILD | GILEAD SCIENCES IN ... | Alton Gregg H | EVP, Corp & Med Af ... | Sell | S | 109.10 | 6,140 | 669,865 | 137,282 | 143.4 K to 137.3 K (-4.28 %) |
Nov 04 2015 | GILD | GILEAD SCIENCES IN ... | Alton Gregg H | EVP, Corp & Med Af ... | Buy | M | 24.30 | 10,000 | 242,950 | 143,422 | 133.4 K to 143.4 K (+7.50 %) |
Nov 04 2015 | GILD | GILEAD SCIENCES IN ... | MARTIN JOHN C | Chairman and CEO | Option Exercise | M | 14.50 | 150,000 | 2,175,375 | 150,000 | |
Nov 04 2015 | GILD | GILEAD SCIENCES IN ... | MARTIN JOHN C | Chairman and CEO | Sell | S | 109.58 | 107,583 | 11,788,827 | 3,948,066 | 4.1 M to 3.9 M (-2.65 %) |
Nov 04 2015 | GILD | GILEAD SCIENCES IN ... | MARTIN JOHN C | Chairman and CEO | Sell | S | 109.02 | 42,417 | 4,624,200 | 4,055,649 | 4.1 M to 4.1 M (-1.04 %) |
Nov 04 2015 | GILD | GILEAD SCIENCES IN ... | MARTIN JOHN C | Chairman and CEO | Buy | M | 14.50 | 150,000 | 2,175,375 | 4,098,066 | 3.9 M to 4.1 M (+3.80 %) |
Oct 28 2015 | GILD | GILEAD SCIENCES IN ... | Cogan John Francis | Director | Option Exercise | M | 20.71 | 15,000 | 310,575 | 30,000 | |
Oct 28 2015 | GILD | GILEAD SCIENCES IN ... | Cogan John Francis | Director | Sell | S | 110.00 | 15,000 | 1,650,000 | 44,309 | 59.3 K to 44.3 K (-25.29 %) |
Oct 28 2015 | GILD | GILEAD SCIENCES IN ... | Cogan John Francis | Director | Buy | M | 20.71 | 15,000 | 310,575 | 59,309 | 44.3 K to 59.3 K (+33.85 %) |
Oct 28 2015 | GILD | GILEAD SCIENCES IN ... | Carter Paul Rutherford | EVP Commercial Ops | Option Exercise | M | 26.99 | 1,500 | 40,485 | 3,007 | |
Oct 28 2015 | GILD | GILEAD SCIENCES IN ... | Carter Paul Rutherford | EVP Commercial Ops | Sell | S | 110.06 | 1,500 | 165,092 | 48,783 | 50.3 K to 48.8 K (-2.98 %) |
Oct 28 2015 | GILD | GILEAD SCIENCES IN ... | Carter Paul Rutherford | EVP Commercial Ops | Sell | M | 26.99 | 1,500 | 40,485 | 50,283 | 51.8 K to 50.3 K (-2.90 %) |
Oct 27 2015 | GILD | GILEAD SCIENCES IN ... | Alton Gregg H | EVP, Corp & Med Af ... | Option Exercise | M | 24.30 | 5,000 | 121,475 | 128,742 | |
Oct 27 2015 | GILD | GILEAD SCIENCES IN ... | Alton Gregg H | EVP, Corp & Med Af ... | Sell | S | 110.00 | 5,000 | 550,000 | 133,422 | 138.4 K to 133.4 K (-3.61 %) |
Oct 27 2015 | GILD | GILEAD SCIENCES IN ... | Alton Gregg H | EVP, Corp & Med Af ... | Buy | M | 24.30 | 5,000 | 121,475 | 138,422 | 133.4 K to 138.4 K (+3.75 %) |
Oct 27 2015 | GILD | GILEAD SCIENCES IN ... | Cogan John Francis | Director | Option Exercise | M | 20.71 | 15,000 | 310,575 | 45,000 | |
Oct 27 2015 | GILD | GILEAD SCIENCES IN ... | Cogan John Francis | Director | Sell | S | 110.00 | 15,000 | 1,650,000 | 44,309 | 59.3 K to 44.3 K (-25.29 %) |
Oct 27 2015 | GILD | GILEAD SCIENCES IN ... | Cogan John Francis | Director | Buy | M | 20.71 | 15,000 | 310,575 | 59,309 | 44.3 K to 59.3 K (+33.85 %) |
Oct 16 2015 | GILD | GILEAD SCIENCES IN ... | BISCHOFBERGER NORBERT W | EVP, R&D and CSO | Option Exercise | M | 23.76 | 1,600 | 38,008 | 142,400 | |
Oct 16 2015 | GILD | GILEAD SCIENCES IN ... | BISCHOFBERGER NORBERT W | EVP, R&D and CSO | Option Exercise | M | 23.60 | 68,400 | 1,614,240 | 0 | |
Oct 16 2015 | GILD | GILEAD SCIENCES IN ... | BISCHOFBERGER NORBERT W | EVP, R&D and CSO | Sell | S | 101.18 | 25,319 | 2,561,749 | 165,168 | 190.5 K to 165.2 K (-13.29 %) |
Oct 16 2015 | GILD | GILEAD SCIENCES IN ... | BISCHOFBERGER NORBERT W | EVP, R&D and CSO | Sell | S | 99.96 | 15,376 | 1,537,000 | 190,487 | 205.9 K to 190.5 K (-7.47 %) |
Oct 16 2015 | GILD | GILEAD SCIENCES IN ... | BISCHOFBERGER NORBERT W | EVP, R&D and CSO | Sell | S | 99.25 | 26,105 | 2,590,817 | 205,863 | 232 K to 205.9 K (-11.25 %) |
Oct 16 2015 | GILD | GILEAD SCIENCES IN ... | BISCHOFBERGER NORBERT W | EVP, R&D and CSO | Sell | S | 98.02 | 3,200 | 313,655 | 231,968 | 235.2 K to 232 K (-1.36 %) |
Oct 16 2015 | GILD | GILEAD SCIENCES IN ... | BISCHOFBERGER NORBERT W | EVP, R&D and CSO | Buy | M | 23.76 | 1,600 | 38,008 | 235,168 | 233.6 K to 235.2 K (+0.69 %) |
Oct 16 2015 | GILD | GILEAD SCIENCES IN ... | BISCHOFBERGER NORBERT W | EVP, R&D and CSO | Buy | M | 23.60 | 68,400 | 1,614,240 | 233,568 | 165.2 K to 233.6 K (+41.41 %) |
Oct 08 2015 | GILD | GILEAD SCIENCES IN ... | MILLIGAN JOHN F | President and COO | Option Exercise | M | 14.50 | 100,000 | 1,450,250 | 200,000 | |
Oct 08 2015 | GILD | GILEAD SCIENCES IN ... | MILLIGAN JOHN F | President and COO | Sell | S | 99.93 | 34,151 | 3,412,709 | 1,029,108 | 1.1 M to 1 M (-3.21 %) |
Oct 08 2015 | GILD | GILEAD SCIENCES IN ... | MILLIGAN JOHN F | President and COO | Sell | S | 99.08 | 50,799 | 5,033,368 | 1,063,259 | 1.1 M to 1.1 M (-4.56 %) |
Oct 08 2015 | GILD | GILEAD SCIENCES IN ... | MILLIGAN JOHN F | President and COO | Sell | S | 98.04 | 15,050 | 1,475,446 | 1,114,058 | 1.1 M to 1.1 M (-1.33 %) |